Antiretroviral agents in persons with HIV with relative contraindications: Are we prescribing in accordance with BHIVA guidelines?

ALAGARATNAM J1, Sabin C1, De Francesco D1, Bagkeris E1, Post F1, Boffito M2, Vera J3, Anderson J3, Williams I3, Johnson M6, Sachkonye M10, Mallon P1, Winston A1,2 on behalf of the POPPY study group

1 Imperial College London, UK, 2 Imperial College Healthcare NHS Trust, UK, 3 University College London, UK, 4 King’s College London, UK, 5 Chelsea & Westminster Hospital NHS Foundation Trust, UK, 6 Barts & The London NHS Trust, UK, 7 Northern University College Foundation Trust, UK, 8 TGH-CAB, London, UK, 9 School of Medicine, University College Dublin, Ireland

Correspondence: j.alagaratnam@imperial.ac.uk

BACKGROUND

While modern ART has improved survival for persons with HIV (PWH), certain ART agents may exacerbate comorbidities.

In the following individuals, and where acceptable alternatives are available, BHIVA treatment guidelines recommend avoidance:

High cardiovascular disease (CVD) risk: abacavir (ABC)

Renal impairment with chronic kidney disease (CKD) stages 3-5: tenofovir-DF (TDF) and/or aztazavir (AZV)

Cognitive impairment and/or current or past history of mental health conditions: efavirenz (EFV)

AIM

To investigate whether PWH in the POPPY study were receiving ART with the relative contraindications highlighted above.

METHODS

PARTICIPANTS

The Pharmacokinetics and clinical Observations in People over fifty (POPPY) study is a multicentre, prospective, observational study assessing clinical outcomes of PWH over the age of 50 in the UK and Ireland (Figure 1).

Participants were recruited between April 2013 – Dec 2015.

Figure 1: Participating centres in the POPPY study

DATA COLLECTION

Information was gathered from POPPY participants via face-to-face interview by trained clinical research staff at the baseline visit, with a focus on comorbidities and medication.

DEFINITIONS OF COMORBIDITIES

High CVD risk:

• 10-year predicted risk >10% on QRISK2 or Framingham risk prediction calculators, or

• a history of ischaemic heart disease (IHD)

Renal impairment with chronic kidney disease (CKD) stages 3-5:

• eGFR <60mL/min/1.73m² (using CKD-EPI calculator)

Cognitive impairment (CI):

• cognitive function scores meeting the HIV-associated neurocognitive disorders (HAND) definition

Symptomatic cognitive impairment (CI):

• subjects with HAND answering ‘yes’ to ≥ 1 Simioni cognitive symptoms questions

Mental health conditions:

• current or previous clinical diagnosis of depression, anxiety, psychotic disorders or sleep disturbances

RESULTS

In total, 1046 POPPY participants were receiving ART at their baseline visit.

Figure 2: Number of POPPY participants on abacavir, tenofovir-DF and/or atazanavir, and efavirenz, respectively.

Participants in the yellow columns are on the ART-regimens above and deemed not to have the relative contraindications being investigated. Participants in the green, purple and red columns are the groups deemed to have high cardiovascular disease risk, renal impairment with chronic kidney disease stages 3-5, and cognitive impairment and/or current or past history of mental health conditions, respectively.

DISCUSSION AND CONCLUSION

Whilst few PWH receiving TDF and/or AZV had renal contraindications, high proportions of those receiving ABC and EFV had high CVD risk and cognitive problems and/or mental health conditions, respectively.

Baseline study visit for all POPPY participants took place prior to the routine availability of tenofovir alafenamide, meaning that participants who received TDF and/or AZV had renal impairment.

LIMITATIONS OF THIS STUDY

The limitations of this study include the lack of longitudinal data, the subjective nature of cognitive symptomology and the relative contraindications were collected as part of study procedures only and results were not relayed back to the treating clinician.

REFERENCES

